Developer docs
API playgroundTry for free, no card

Search company profiles

ScitoVation

Full company profile

uuid00043n2

Namestring
ScitoVation
Legal namestring
SCITOVATION, LLC.
Websiteurl
scitovation.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

ScitoVation, LLC is a contract research organization (CRO) headquartered in Durham, North Carolina, specializing in chemical safety assessment for pharmaceuticals, chemicals, food ingredients, cosmetics, agricultural chemicals, and consumer products using New Approach Methods (NAMs) that replace traditional animal testing with cell-based and computational techniques. The company was founded in 2016 by principals whose predecessor organization contributed to the National Academy of Sciences 2007 report "Toxicity Testing in the 21st Century," giving it a 40+ year lineage of expertise in regulatory toxicology. Its core technology portfolio centers on PLETHEM, an open-source physiologically based pharmacokinetic (PBPK) modeling platform developed under a memorandum of understanding with the US Environmental Protection Agency and comprising integrated modules for rapid PBPK, high-throughput in vitro to in vivo extrapolation (IVIVE), kinetically derived maximum dose (KMD) modeling, chemical clearance prediction, and ecotoxicological PBPK. Supporting tools include MoAViz (a mode-of-action gene expression visualization database), the TTC Data Mart (a 45,000-compound threshold of toxicological concern database), and the forthcoming ScitoSim AI Platform for predictive toxicology. The TgX DDI transcriptomic biomarker is currently undergoing FDA validation for genotoxicity assessment.

The company serves three primary verticals: pharmaceutical companies (lead compound screening, genotoxicity assessment, PBPK modeling for dose prediction, drug-drug interaction simulation), chemical manufacturers and consumer product companies (chemical safety assessment, NAMs implementation, regulatory submissions), and industry associations such as the American Chemistry Council, American Beverage Association, Cosmetic Europe, CAPHRA, RIFM, and NiPERA (consortium-funded research on member-relevant compounds). ScitoVation generates revenue through fee-for-service contract research priced via a Request For Quote process with multi-year project terms, supplemented by Small Business Innovation Research (SBIR) grants from the National Institute of Environmental Health Sciences (NIEHS). In February 2025 the company announced a strategic shift to focus exclusively on computational toxicology, concluding laboratory operations on March 31, 2025, and in November 2025 deepened a strategic partnership with Integral Consulting to deploy AI- and NAM-based chemical safety tools.

Short descriptiontext

ScitoVation is a Durham, NC-based CRO that uses New Approach Methods (NAMs), PBPK modeling, and AI to assess chemical safety for pharmaceutical, chemical, consumer product, and industry association clients, replacing animal testing with computational and cell-based approaches.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational toxicology, PBPK modeling, chemical safety assessment, in vitro assays, new approach methodologies
Industry1 code
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Contract Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

ScitoVation operates as a CRO providing fee-for-service research to assess chemical compound safety for pharmaceuticals, chemicals, food ingredients, cosmetics, and consumer products. Services include PBPK modeling, IVIVE, transcriptomics, cell-based assays, and genotoxicity testing.

scitovation.com
2Government Research Grants
TypeLicensing Royalties
Description

SBIR awards from National Institute of Environmental Health Sciences (NIEHS) to develop computational solutions for predicting human health effects.

prweb.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Project types include In Vitro Studies, Micronucleus, PBPK modeling, and Transcriptomics. Pricing varies based on number of compounds, dose per compounds, number of cell lines, and whether sequencing data is provided by client or needs to be extracted by ScitoVation.

scitovation.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1MoAViz
Description

Mode of Action Visualization tool - a database and visualization platform for comparing gene expression changes in response to chemical exposures in different model systems.

scitovation.com
+3 more records
Core offering1 text field

ScitoVation is a contract research organization (CRO) that helps clients assess the safety of pharmaceuticals, chemicals, food ingredients, cosmetics, and consumer products using new approach methods (NAMs) including cell-based assays, computational toxicology, PBPK modeling, and transcriptomics. The company offers a unified platform-plus-services model combining proprietary software tools (PLETHEM, MoAViz, TTC Data Mart, ScitoSim AI) with laboratory and computational research services for chemical safety assessment and regulatory submission support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Removed artificial adjustment factor for children in pyrethroid risk assessment after EPA review of ScitoVation's PBPK modeling
+2 more records
Product overview1 text field

ScitoVation is a contract research organization (CRO) offering a unified platform-plus-services model for chemical safety assessment. The core technology portfolio centers on PLETHEM, an open-source PBPK modeling platform, complemented by specialized tools including MoAViz (mode of action visualization), TTC Data Mart (threshold of toxicological concern), and ScitoSim™ AI Platform. ScitoVation provides laboratory services including in vitro compound screening, micronucleus assays, gene expression analysis, and hypothesis testing via RNAi/CRISPR, alongside computational services spanning PBPK modeling, IVIVE, toxicogenomic studies, and AI-assisted literature review. The offering integrates the PLETHEM modules (RapidPBPK, HT-IVIVE, KMD, Clearance Tool, Ecotox PBPK) with wet-lab capabilities and the new DRIIVE developmental platform to provide end-to-end NAM-based risk assessment.

Product and service16 records
1PLETHEM (Population Life-course exposure to Health Effects Model)
CategoryComputational Toxicology Software
Description

Flexible open-source PBPK modeling platform combining high-throughput exposure prediction and rapid physiologically-based pharmacokinetic modeling for chemical dosimetry and risk assessment, developed under memorandum of understanding with US EPA.

2MoAViz (Mode of Action Visualization)
CategoryComputational Toxicology Software
Description

Interactive database and visualization tool for comparing gene expression changes in response to chemical exposures across different model systems and exposure scenarios.

3TTC Data Mart (Threshold of Toxicological Concern)
4ScitoSim AI Platform
CategoryAI Platform
Description

Next-generation AI platform for predictive toxicology, leveraging advanced molecular and computational toxicology tools to predict human health effects through NAMs.

5DRIIVE (Developmental PBPK/IVIVE Platform)
CategoryComputational Toxicology Software
Description

Developmental PBPK/IVIVE platform for traceable, regulator-ready evidence pipelines supporting developmental and reproductive toxicology assessments.

6PBPK Modeling Services
CategoryContract Research Services
Description

Physiologically-based pharmacokinetic modeling for interspecies extrapolation, intra-species variability, route-to-route extrapolation, high-to-low dose extrapolation, and population variability assessment.

7IVIVE Services
CategoryContract Research Services
Description

In vitro to in vivo extrapolation for translating large-scale in vitro toxicity assay results into in vivo exposure context, including high-throughput IVIVE and quantitative IVIVE (Q-IVIVE).

8Toxicogenomic Studies
CategoryContract Research Services
Description

Cutting-edge technologies for probing molecular changes to identify perturbations related to apical effects using Adverse Outcome Pathway frameworks.

9Compound Screening Service
CategoryContract Research Services
Description

In vitro cell-based assays for go/no-go decision making, compound ranking by cytotoxicity, and range-finding for concentrations in complex experiments, screening up to 30 compounds per batch.

10Lead Compound Assessment
CategoryContract Research Services
Description

Characterization of safety endpoints including cell viability, cell cycle, kinetic proliferation, integrated stress response, and mitochondrial fragmentation using high-content imaging (Phoenix Opera).

11Micronucleus Assay
CategoryContract Research Services
Description

Flow cytometry-based in vitro micronucleus assay using human TK6 or HepaRG cells for genotoxicity assessment compliant with OECD 487.

12QSAR Mutagenicity Screening
CategoryContract Research Services
Description

Computational tools based on compound structure highly predictive of bacterial mutagenicity testing (Ames Test) for early candidate triage.

13Gene Expression Analysis
CategoryContract Research Services
Description

Differential gene expression analysis using qRT-PCR (targeted) and RNA-seq (omics scale) with computational expertise for developing biologically meaningful hypotheses.

14Hypothesis Testing (RNAi and Gene Editing)
CategoryContract Research Services
Description

Protein expression manipulation through lentiviral transduction for overexpression/shRNA knockdown and CRISPR/Cas9 for knockout cell lines.

15Custom Assays
CategoryContract Research Services
Description

Bespoke cell-based assays designed to measure specific mode of action endpoints, including steatosis and uterine assays.

16AI-Assisted Literature Review
CategoryContract Research Services
Description

Research scientist-led initiative to modernize toxicology evidence gathering through automation and AI-assisted curation for DART, IVIVE, and PBPK modeling.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Deepened strategic partnership deploying advanced molecular and computational toxicology tools using AI and NAMs to accelerate chemical safety assessments. Integrated tools enhance toxicology, pharmacokinetics, exposure, and risk assessment processes for faster chemical safety decisions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-12
Description

Strategic alliance to advance innovation in health risk assessment, combining ScitoVation's computational toxicology expertise with Integral Consulting's engineering and environmental science capabilities.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Active participation in committees developing standards for regulatory submission of PBPK models. Collaboration yielded a consensus paper on transcriptomics, inhalation, and genotoxicity methods.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with MIT and University of Ottawa (Carole Yauk) to develop a human-relevant genotoxicity testing platform using metabolically competent human hepatocytes integrated with rapid detection of genotoxicity and mode-of-action based genomic profiling.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Dr. Leslie Recio serves on this working group since 2014, contributing to international standards for genetic toxicology testing.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborated on PBPK model development under memorandum of understanding. EPA Office of Pesticides utilizes PLETHEM as open-source platform for evaluations. ScitoVation data submitted to EPA influenced regulatory decisions on pyrethroids.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Private toxicology and risk assessment consulting firm offering PBPK modeling, mode-of-action, and regulatory toxicology services to chemicals, pharma, and consumer products clients. Closely comparable in scope, client mix, and service model to ScitoVation's NAMs offering.

TypeDirect peer
Description

Preclinical and genetic toxicology CRO where ScitoVation's CSO Dr. Leslie Recio previously served as CSO/Director. Provides genetic toxicology, regulatory toxicology, and NTP-aligned testing — overlapping directly with ScitoVation's genotoxicity and OECD-submission capabilities.

TypeBroad incumbent
Description

Global engineering and environmental consulting firm whose health sciences practice conducts chemical risk assessment, exposure science, and toxicology for industrial and government clients — increasingly intersecting with NAMs work.

TypeRegional player
Description

Research Triangle Park-based nonprofit research institute with significant environmental health, statistical, and toxicology capabilities. Geographic and talent-market overlap with ScitoVation, and competing for federal grants and chemical-industry research dollars.

TypeDirect peer
Description

Environmental and human health risk assessment consultancy providing toxicology, exposure, and PBPK modeling services to chemical, consumer products, and legal clients. Highly comparable boutique competitor in the same NAMs/mode-of-action space.

TypeBroad incumbent
Description

One of the largest preclinical CROs globally with deep safety assessment, genetic toxicology, and PBPK capabilities. Competes with ScitoVation for outsourced chemical and pharmaceutical safety work but at substantially greater scale.

TypeDirect peer
Description

Toxicology and risk assessment consulting practice providing chemical safety, exposure, and PBPK services to industry and legal clients. Comparable boutique in NAMs, mode-of-action, and regulatory toxicology.

TypeBroad incumbent
Description

Integrated CRO with significant in vitro/in vivo toxicology, DMPK/PBPK, and computational toxicology capabilities serving both pharmaceutical and chemical clients. Competes for outsourced safety assessment and PBPK modeling engagements.

TypeBroad incumbent
Description

Large engineering and scientific consulting firm with a health sciences practice that conducts toxicology, PBPK, and risk assessment work for chemicals, pharma, and product liability clients. A broader, more diversified competitor operating in overlapping NAMs engagements.

TypeBroad incumbent
Description

Large nonprofit contract research organization with a dedicated life sciences and toxicology practice. Competes for government and chemical-industry toxicology contracts and operates in adjacent areas such as inhalation toxicology, environmental health, and PBPK modeling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ScitoVation

Contract Research Servicesscitovation.com

ScitoVation is a Durham, NC-based CRO that uses New Approach Methods (NAMs), PBPK modeling, and AI to assess chemical safety for pharmaceutical, chemical, consumer product, and industry association clients, replacing animal testing with computational and cell-based approaches.

What ScitoVation does

ScitoVation, LLC is a contract research organization (CRO) headquartered in Durham, North Carolina, specializing in chemical safety assessment for pharmaceuticals, chemicals, food ingredients, cosmetics, agricultural chemicals, and consumer products using New Approach Methods (NAMs) that replace traditional animal testing with cell-based and computational techniques. The company was founded in 2016 by principals whose predecessor organization contributed to the National Academy of Sciences 2007 report "Toxicity Testing in the 21st Century," giving it a 40+ year lineage of expertise in regulatory toxicology. Its core technology portfolio centers on PLETHEM, an open-source physiologically based pharmacokinetic (PBPK) modeling platform developed under a memorandum of understanding with the US Environmental Protection Agency and comprising integrated modules for rapid PBPK, high-throughput in vitro to in vivo extrapolation (IVIVE), kinetically derived maximum dose (KMD) modeling, chemical clearance prediction, and ecotoxicological PBPK. Supporting tools include MoAViz (a mode-of-action gene expression visualization database), the TTC Data Mart (a 45,000-compound threshold of toxicological concern database), and the forthcoming ScitoSim AI Platform for predictive toxicology. The TgX DDI transcriptomic biomarker is currently undergoing FDA validation for genotoxicity assessment.

The company serves three primary verticals: pharmaceutical companies (lead compound screening, genotoxicity assessment, PBPK modeling for dose prediction, drug-drug interaction simulation), chemical manufacturers and consumer product companies (chemical safety assessment, NAMs implementation, regulatory submissions), and industry associations such as the American Chemistry Council, American Beverage Association, Cosmetic Europe, CAPHRA, RIFM, and NiPERA (consortium-funded research on member-relevant compounds). ScitoVation generates revenue through fee-for-service contract research priced via a Request For Quote process with multi-year project terms, supplemented by Small Business Innovation Research (SBIR) grants from the National Institute of Environmental Health Sciences (NIEHS). In February 2025 the company announced a strategic shift to focus exclusively on computational toxicology, concluding laboratory operations on March 31, 2025, and in November 2025 deepened a strategic partnership with Integral Consulting to deploy AI- and NAM-based chemical safety tools.

ScitoVation firmographics

Firmographics
Name
ScitoVation
Legal name
SCITOVATION, LLC.
Website
https://scitovation.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
ScitoVation is a Durham, NC-based CRO that uses New Approach Methods (NAMs), PBPK modeling, and AI to assess chemical safety for pharmaceutical, chemical, consumer product, and industry association clients, replacing animal testing with computational and cell-based approaches.
Ownership category
akta.pro rank

ScitoVation industry classification

Industry
Product category
Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)

Keywords

  • Computational toxicology
  • PBPK modeling
  • Chemical safety assessment
  • In vitro assays
  • New approach methodologies

Where ScitoVation is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

ScitoVation business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Contract Research Services: ScitoVation operates as a CRO providing fee-for-service research to assess chemical compound safety for pharmaceuticals, chemicals, food ingredients, cosmetics, and consumer products. Services include PBPK modeling, IVIVE, transcriptomics, cell-based assays, and genotoxicity testing.
  2. Government Research Grants: SBIR awards from National Institute of Environmental Health Sciences (NIEHS) to develop computational solutions for predicting human health effects.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

ScitoVation product offering

Product offering

Core offering

ScitoVation is a contract research organization (CRO) that helps clients assess the safety of pharmaceuticals, chemicals, food ingredients, cosmetics, and consumer products using new approach methods (NAMs) including cell-based assays, computational toxicology, PBPK modeling, and transcriptomics. The company offers a unified platform-plus-services model combining proprietary software tools (PLETHEM, MoAViz, TTC Data Mart, ScitoSim AI) with laboratory and computational research services for chemical safety assessment and regulatory submission support.

Product overview

ScitoVation is a contract research organization (CRO) offering a unified platform-plus-services model for chemical safety assessment. The core technology portfolio centers on PLETHEM, an open-source PBPK modeling platform, complemented by specialized tools including MoAViz (mode of action visualization), TTC Data Mart (threshold of toxicological concern), and ScitoSim™ AI Platform. ScitoVation provides laboratory services including in vitro compound screening, micronucleus assays, gene expression analysis, and hypothesis testing via RNAi/CRISPR, alongside computational services spanning PBPK modeling, IVIVE, toxicogenomic studies, and AI-assisted literature review. The offering integrates the PLETHEM modules (RapidPBPK, HT-IVIVE, KMD, Clearance Tool, Ecotox PBPK) with wet-lab capabilities and the new DRIIVE developmental platform to provide end-to-end NAM-based risk assessment.

Differentiator

Problem solved

Functional benefit

Brands

  • MoAViz: Mode of Action Visualization tool - a database and visualization platform for comparing gene expression changes in response to chemical exposures in different model systems.
  • PLETHEM
  • TTC Data Mart
  • ScitoSim™

Products and services

  • PLETHEM (Population Life-course exposure to Health Effects Model) Flexible open-source PBPK modeling platform combining high-throughput exposure prediction and rapid physiologically-based pharmacokinetic modeling for chemical dosimetry and risk assessment, developed under memorandum of understanding with US EPA.
  • MoAViz (Mode of Action Visualization) Interactive database and visualization tool for comparing gene expression changes in response to chemical exposures across different model systems and exposure scenarios.
  • TTC Data Mart (Threshold of Toxicological Concern)
  • ScitoSim AI Platform Next-generation AI platform for predictive toxicology, leveraging advanced molecular and computational toxicology tools to predict human health effects through NAMs.
  • DRIIVE (Developmental PBPK/IVIVE Platform) Developmental PBPK/IVIVE platform for traceable, regulator-ready evidence pipelines supporting developmental and reproductive toxicology assessments.
  • PBPK Modeling Services Physiologically-based pharmacokinetic modeling for interspecies extrapolation, intra-species variability, route-to-route extrapolation, high-to-low dose extrapolation, and population variability assessment.
  • IVIVE Services In vitro to in vivo extrapolation for translating large-scale in vitro toxicity assay results into in vivo exposure context, including high-throughput IVIVE and quantitative IVIVE (Q-IVIVE).
  • Toxicogenomic Studies Cutting-edge technologies for probing molecular changes to identify perturbations related to apical effects using Adverse Outcome Pathway frameworks.
  • Compound Screening Service In vitro cell-based assays for go/no-go decision making, compound ranking by cytotoxicity, and range-finding for concentrations in complex experiments, screening up to 30 compounds per batch.
  • Lead Compound Assessment Characterization of safety endpoints including cell viability, cell cycle, kinetic proliferation, integrated stress response, and mitochondrial fragmentation using high-content imaging (Phoenix Opera).
  • Micronucleus Assay Flow cytometry-based in vitro micronucleus assay using human TK6 or HepaRG cells for genotoxicity assessment compliant with OECD 487.
  • QSAR Mutagenicity Screening Computational tools based on compound structure highly predictive of bacterial mutagenicity testing (Ames Test) for early candidate triage.
  • Gene Expression Analysis Differential gene expression analysis using qRT-PCR (targeted) and RNA-seq (omics scale) with computational expertise for developing biologically meaningful hypotheses.
  • Hypothesis Testing (RNAi and Gene Editing) Protein expression manipulation through lentiviral transduction for overexpression/shRNA knockdown and CRISPR/Cas9 for knockout cell lines.
  • Custom Assays Bespoke cell-based assays designed to measure specific mode of action endpoints, including steatosis and uterine assays.
  • AI-Assisted Literature Review Research scientist-led initiative to modernize toxicology evidence gathering through automation and AI-assisted curation for DART, IVIVE, and PBPK modeling.

Quantifiable outcome

  • Removed artificial adjustment factor for children in pyrethroid risk assessment after EPA review of ScitoVation's PBPK modeling
  • +2 more outcomes

Companies that use ScitoVation

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

ScitoVation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

ScitoVation partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • Integral Consulting Inc.coreStrategic or Co-development Partner · 18 November 2025Deepened strategic partnership deploying advanced molecular and computational toxicology tools using AI and NAMs to accelerate chemical safety assessments. Integrated tools enhance toxicology, pharmacokinetics, exposure, and risk assessment processes for faster chemical safety decisions.
  • Integral Consulting Inc.coreStrategic or Co-development Partner · 12 March 2025Strategic alliance to advance innovation in health risk assessment, combining ScitoVation's computational toxicology expertise with Integral Consulting's engineering and environmental science capabilities.
  • HESI (Health and Environmental Sciences Institute)majorStrategic or Co-development PartnerActive participation in committees developing standards for regulatory submission of PBPK models. Collaboration yielded a consensus paper on transcriptomics, inhalation, and genotoxicity methods.
  • MIT (Bevin Engelward)majorStrategic or Co-development PartnerCollaboration with MIT and University of Ottawa (Carole Yauk) to develop a human-relevant genotoxicity testing platform using metabolically competent human hepatocytes integrated with rapid detection of genotoxicity and mode-of-action based genomic profiling.
  • OECD Genetic Toxicology Expert Working GroupmajorStrategic or Co-development PartnerDr. Leslie Recio serves on this working group since 2014, contributing to international standards for genetic toxicology testing.
  • US Environmental Protection Agency (EPA)majorStrategic or Co-development PartnerCollaborated on PBPK model development under memorandum of understanding. EPA Office of Pesticides utilizes PLETHEM as open-source platform for evaluations. ScitoVation data submitted to EPA influenced regulatory decisions on pyrethroids.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

ScitoVation competitors and assessment

Company assessment

Direct peers

  • ToxStrategies: Private toxicology and risk assessment consulting firm offering PBPK modeling, mode-of-action, and regulatory toxicology services to chemicals, pharma, and consumer products clients. Closely comparable in scope, client mix, and service model to ScitoVation's NAMs offering.
  • Inotiv (formerly ILS): Preclinical and genetic toxicology CRO where ScitoVation's CSO Dr. Leslie Recio previously served as CSO/Director. Provides genetic toxicology, regulatory toxicology, and NTP-aligned testing — overlapping directly with ScitoVation's genotoxicity and OECD-submission capabilities.
  • Gradient Analytics: Environmental and human health risk assessment consultancy providing toxicology, exposure, and PBPK modeling services to chemical, consumer products, and legal clients. Highly comparable boutique competitor in the same NAMs/mode-of-action space.
  • Cardno ChemRisk: Toxicology and risk assessment consulting practice providing chemical safety, exposure, and PBPK services to industry and legal clients. Comparable boutique in NAMs, mode-of-action, and regulatory toxicology.

Broad incumbents

  • Ramboll (Environ): Global engineering and environmental consulting firm whose health sciences practice conducts chemical risk assessment, exposure science, and toxicology for industrial and government clients — increasingly intersecting with NAMs work.
  • Charles River Laboratories: One of the largest preclinical CROs globally with deep safety assessment, genetic toxicology, and PBPK capabilities. Competes with ScitoVation for outsourced chemical and pharmaceutical safety work but at substantially greater scale.
  • Pharmaron: Integrated CRO with significant in vitro/in vivo toxicology, DMPK/PBPK, and computational toxicology capabilities serving both pharmaceutical and chemical clients. Competes for outsourced safety assessment and PBPK modeling engagements.
  • Exponent: Large engineering and scientific consulting firm with a health sciences practice that conducts toxicology, PBPK, and risk assessment work for chemicals, pharma, and product liability clients. A broader, more diversified competitor operating in overlapping NAMs engagements.
  • Battelle: Large nonprofit contract research organization with a dedicated life sciences and toxicology practice. Competes for government and chemical-industry toxicology contracts and operates in adjacent areas such as inhalation toxicology, environmental health, and PBPK modeling.

Regional players

  • RTI International: Research Triangle Park-based nonprofit research institute with significant environmental health, statistical, and toxicology capabilities. Geographic and talent-market overlap with ScitoVation, and competing for federal grants and chemical-industry research dollars.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

ScitoVation social profiles

Digital presence

ScitoVation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ScitoVation leadership team

Management profile

Number of profiles

Profiles6 records

ScitoVation funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ScitoVation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ScitoVation

What does ScitoVation do?

ScitoVation is a contract research organization (CRO) that helps clients assess the safety of pharmaceuticals, chemicals, food ingredients, cosmetics, and consumer products using new approach methods (NAMs) including cell-based assays, computational toxicology, PBPK modeling, and transcriptomics. The company offers a unified platform-plus-services model combining proprietary software tools (PLETHEM, MoAViz, TTC Data Mart, ScitoSim AI) with laboratory and computational research services for chemical safety assessment and regulatory submission support.

Is ScitoVation a public or private company?

ScitoVation is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ScitoVation founded?

ScitoVation was founded in 2016. It employs 11 to 50 people.

Where is ScitoVation based?

ScitoVation is headquartered in Durham, United States, in the North America region.

How does ScitoVation make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are government Research Grants.

Who are ScitoVation's main competitors?

Direct peers on record are ToxStrategies, Inotiv (formerly ILS), Gradient Analytics and Cardno ChemRisk. Broad incumbents are Ramboll (Environ), Charles River Laboratories, Pharmaron, Exponent and Battelle. RTI International is listed as a regional player.

Does ScitoVation have an API?

No public API is recorded for ScitoVation.

What industry is ScitoVation in?

ScitoVation's product category is Contract Research Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireIntegral Consulting and ScitoVation Deepen Strategic Partnership, Develop Faster Chemical Safety Decisions, Using Advanced Molecular and Computational Toxicology ToolsIntegral Consulting Inc. and ScitoVation announced the successful deployment of AI-powered molecular and computational toxicology tools using new approach methodologies (NAMs) to accelerate chemical safety assessments, marking the renewal of their strategic alliance. The updated portfolio includes AI-powered safety assessment tools, advanced omics analytics, and integrated pharmacokinetic modeling that support applications across consumer products, industrial chemicals, pharmaceuticals, and specialty materials. The companies claim the tools offer faster timelines, lower costs, and stronger scientific defensibility for clients navigating regulatory and real-world use questions.ScitovationScitoVation recipient of $269,977 from NIEHSScitoVation received a $269,977 SBIR Phase I grant from the National Institute of Environmental Health Sciences to develop a computational model for predicting developmental toxicity. The project aims to create an in vitro-to-in vivo extrapolation tool that integrates pharmacokinetic models to reduce reliance on animal testing.PrwebScitoVation Recipient of the National Institute of Environmental Health Science Small Business Innovation Reward Award Phase I for $269,977ScitoVation has been awarded a Phase I Small Business Innovation Research grant worth $269,977 from the National Institute of Environmental Health Sciences. The funding will support the development of a computational solution designed to predict human health effects by performing in vitro-to-in vivo extrapolation for developmental toxicity.PR NewswireScitoVation Announces Release of PLETHEM: Software to Integrate Chemical Exposures and Health EffectsScitoVation announced the release of PLETHEM (Population Lifecourse Exposure-To-Health-Effects Model), a free open-source software platform for pharmacokinetic modeling that bridges external chemical exposure and internal dose to evaluate potential health effects at realistic exposure levels. The tool was funded by the American Chemistry Council's Long-Range Research Initiative and developed through collaboration with scientists at the US Environmental Protection Agency, linking to EPA's existing HTTK R package. PLETHEM features a menu-driven interface designed to make physiologically-based pharmacokinetic modeling accessible to non-expert practitioners in chemical safety decision-making.